Neurocrine Biosciences
 |
|
| Public NASDAQ: NBIX | |
| Industry | Biotechnology |
| Founded | 1992 |
| Headquarters | San Diego, California, U.S. |
|
Key people
|
Bill Rastetter, Chairman Kevin C. Gorman, CEO David-Alexandre Gros, COO/President |
|
Number of employees
|
95 (2015) |
| Website | www.neurocrine.com |
Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and located in San Diego, California. The company took its name from the original focus on therapies for neurological and endocrine diseases and disorders.
On May 16, 2006 when the Food and Drug Administration (FDA) denied approval for the 15-milligram dose of Indiplon, a medication to treat insomnia. Neurocrine had developed the drug and was seeking to market it with partner Pfizer. As a result of the denial, the stock price fell significantly and the company laid off 300 employees in 2006. In 2007 Neurocrine showed a fourth quarter loss of $128 million, including a $94 million write-off, with a further layoff of half the remaining workforce.
In 2010 the company announced that its drug to treat endometriosis had achieved its main and secondary goals in a study. The drug, called elagolix, reportedly showed statistically significant reductions in dysmenorrhea, or pelvic pain during menstruation as well as painful intercourse. As of 2016 the drug, being developed in cooperation with AbbVie, is in phase III clinical trials.
In April of 2017 The United States Food and Drug Administration approved Ingrezza for the treatment of tardive dyskinesia. At the time of approval, it was the only drug that can treat tardive dyskinesia.
...
Wikipedia